These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 27519213)
1. DNA Topoisomerase II-alpha as a marker of cell proliferation in endocrine and other neoplasms. Holden JA Endocr Pathol; 1999 Jun; 10(2):97-102. PubMed ID: 27519213 [TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Holden JA; Townsend JJ Mod Pathol; 1999 Dec; 12(12):1094-100. PubMed ID: 10619260 [TBL] [Abstract][Full Text] [Related]
3. Human DNA topoisomerase II-alpha. Martinchick J; Rahn M; Jolles C; Holden J Int J Oncol; 1997 Jun; 10(6):1229-34. PubMed ID: 21533509 [TBL] [Abstract][Full Text] [Related]
4. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon. Staley BE; Samowitz WS; Bronstein IB; Holden JA Mod Pathol; 1999 Apr; 12(4):356-61. PubMed ID: 10229499 [TBL] [Abstract][Full Text] [Related]
5. Human DNA-Topoisomerases - Diagnostic and Therapeutic Implications for Cancer. Kellner U; Rudolph P; Parwaresch R Onkologie; 2000 Oct; 23(5):424-430. PubMed ID: 11441236 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas. Coleman LW; Bronstein IB; Holden JA Anticancer Res; 2001; 21(2A):1167-72. PubMed ID: 11396158 [TBL] [Abstract][Full Text] [Related]
7. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers. Kim R; Ohi Y; Inoue H; Toge T Anticancer Res; 1999; 19(6B):5393-8. PubMed ID: 10697567 [TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Nakopoulou L; Lazaris AC; Kavantzas N; Alexandrou P; Athanassiadou P; Keramopoulos A; Davaris P Pathobiology; 2000; 68(3):137-43. PubMed ID: 11174071 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Holden JA; Perkins SL; Snow GW; Kjeldsberg CR Am J Clin Pathol; 1995 Jul; 104(1):54-9. PubMed ID: 7611182 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor. Tanoguchi K; Sasano H; Yabuki N; Kikuchi A; Ito K; Sato S; Yajima A Mod Pathol; 1998 Feb; 11(2):186-93. PubMed ID: 9504690 [TBL] [Abstract][Full Text] [Related]
11. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs. Holden JA Ann Clin Lab Sci; 1997; 27(6):402-12. PubMed ID: 9433537 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521 [TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas. Villman K; Ståhl E; Liljegren G; Tidefelt U; Karlsson MG Mod Pathol; 2002 May; 15(5):486-91. PubMed ID: 12011253 [TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance. Wilson CS; Medeiros LJ; Lai R; Butch AW; McCourty A; Kelly K; Brynes RK Mod Pathol; 2001 Sep; 14(9):886-91. PubMed ID: 11557785 [TBL] [Abstract][Full Text] [Related]
15. Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. Tortora G; Ciardiello F; Damiano V; Pepe S; Bianco C; di Isernia G; Davies SL; North P; Harris AL; Hickson ID Clin Cancer Res; 1995 Jan; 1(1):49-56. PubMed ID: 9815886 [TBL] [Abstract][Full Text] [Related]
16. Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival. Gupta D; Bronstein IB; Holden JA Hum Pathol; 2000 Feb; 31(2):214-9. PubMed ID: 10685636 [TBL] [Abstract][Full Text] [Related]
17. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas. Koshiyama M; Fujii H; Kinezaki M; Yoshida M Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183 [TBL] [Abstract][Full Text] [Related]
18. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337 [TBL] [Abstract][Full Text] [Related]
19. Differential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas. Bauman ME; Holden JA; Brown KA; Harker WG; Perkins SL Mod Pathol; 1997 Mar; 10(3):168-75. PubMed ID: 9071722 [TBL] [Abstract][Full Text] [Related]